Just for you, Marvin.PD1-Vaxx - A Timeline14-Jul-2020 -...

Just for you, Marvin.

PD1-Vaxx - A Timeline

14-Jul-2020 - 3.4c

Ethics approval to commence trial.

https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02254667-2BE3RIII073UUCEKJ20M94KTPQ/pdf?access_token=0007O0GNIlprvB96s1T8f7Z4fKBf
17-Jul-2020 - 3.8c

Second ethics approval received.

https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02256025-780RB8K0AQKAUIIRJJON4CG3U3/pdf?access_token=0007O0GNIlprvB96s1T8f7Z4fKBf
21-Aug-2020 - 5.7c

Third ethics approval received.

https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02269752-3RDL40BM33LKIFVOQ54E2MQ9A1/pdf?access_token=0007O0GNIlprvB96s1T8f7Z4fKBf

3-Sep-2020 - 5.3c

US ethics approval received.

https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02276976-6AMQ8C74OVU75V4APBABR3A9Q3/pdf?access_token=0007O0GNIlprvB96s1T8f7Z4fKBf

2-Nov-2020 - 5.6c

US IND approval received

https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02303391-162SH7IECSQI4EUT5EKDLNKKGF/pdf?access_token=0007O0GNIlprvB96s1T8f7Z4fKBf1-Dec-2020 - 13.0c

First patient dosed (5 months after receiving first ethics approval.

https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02316433-0N0D6N2H82QT74OC5GSSE44EP5/pdf?access_token=0007O0GNIlprvB96s1T8f7Z4fKBf17-Dec-2020 - 9.9c

First cohort enrolled.

https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02323466-0VVGKNPA6NGA47R56T5OKOQTHJ/pdf?access_token=0007O0GNIlprvB96s1T8f7Z4fKBf21-Jan-2020 - 12c

Dose escalation to commence.

https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02332480-2E96TL9C5FJJTQ5RNTRSMOEMFE/pdf?access_token=0007O0GNIlprvB96s1T8f7Z4fKBf12-Feb-2021 - 10c

First patient in second dose cohort dosed.

https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02340540-2T3QCAIAFU2UVI60MKBOVBBHVU/pdf?access_token=0007O0GNIlprvB96s1T8f7Z4fKBf

27-Aug-2021 - 34.5c

Third dose cohort to commence.

https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02413211-2QPSOEULUITVCL5NFB4L5C19H0/pdf?access_token=0007O0GNIlprvB96s1T8f7Z4fKBf4-Jan-2022 - 42.5c

P1a monotherapy dose escalation completed. Noting that in a later data release, only 14 patients from a planned 19-28 patients were included in this P1a cohort - this was not mentioned by IMU in this announcement.

https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02472681-117J1VITR4FQVKUO40BTOBG4JC/pdf?access_token=0007O0GNIlprvB96s1T8f7Z4fKBf8-Aug-2022 - 28.5c

IMU presents data on the 14 P1a trial participants. Note that one patient had died due to Immune-mediated pneumonitis elicited by PD1-Vaxx.

https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02550704-0PTPS67BSNUFBEQFNBEA92J4NI/pdf?access_token=0007O0GNIlprvB96s1T8f7Z4fKBf1-Jun-2023 - 10c

First patient dosed in P1b combination arm. That's 18 months after the P1a was completed.

https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02671929-6L6QLSS7N0D2IG671SJLSK2T22/pdf?access_token=0007O0GNIlprvB96s1T8f7Z4fKBf